Reported 1 day ago
Regeneron Pharmaceuticals, Inc. has announced the acquisition of most of 23andMe’s assets for $256 million, including its personal genome services and biobank. This deal will significantly enhance Regeneron's genetic data capabilities, expanding its repository from 3 million to 15 million individuals' genomic information, thus strengthening its position in genetic-driven drug development and precision medicine.
Source: YAHOO